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Background: Amblyopia is the commonest visual disorder of childhood in Western societies, affecting, predominantly,
spatial visual function. Treatment typically requires a period of refractive correction (‘optical treatment’) followed by
occlusion: covering the nonamblyopic eye with a fabric patch for varying daily durations. Recent studies have provided
insight into the optimal amount of patching (‘dose’), leading to the adoption of standardized dosing strategies, which,
though an advance on previous ad-hoc regimens, take little account of individual patient characteristics. This trial
compares the effectiveness of a standardized dosing strategy (that is, a fixed daily occlusion dose based on disease
severity) with a personalized dosing strategy (derived from known treatment dose-response functions), in which an
initially prescribed occlusion dose is modulated, in a systematic manner, dependent on treatment compliance.
Methods/design: A total of 120 children aged between 3 and 8 years of age diagnosed with amblyopia in association
with either anisometropia or strabismus, or both, will be randomized to receive either a standardized or a personalized
occlusion dose regimen. To avoid confounding by the known benefits of refractive correction, participants will not be
randomized until they have completed an optical treatment phase. The primary study objective is to determine
whether, at trial endpoint, participants receiving a personalized dosing strategy require fewer hours of occlusion than
those in receipt of a standardized dosing strategy. Secondary objectives are to quantify the relationship between
observed changes in visual acuity (logMAR, logarithm of the Minimum Angle of Resolution) with age, amblyopia type,
and severity of amblyopic visual acuity deficit.
Discussion: This is the first randomized controlled trial of occlusion therapy for amblyopia to compare a treatment arm
representative of current best practice with an arm representative of an entirely novel treatment regimen based on
statistical modelling of previous trial outcome data. Should the personalized dosing strategy demonstrate superiority
over the standardized dosing strategy, then its adoption into routine practice could bring practical benefits in reducing
the duration of treatment needed to achieve an optimal outcome.
Trial registration: ISRCTN ISRCTN12292232.
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Amblyopia is the commonest visual disorder of child-
hood in developed nations, with an estimated prevalence
of 1.6 to 3.5% [1]. Principally manifesting as a deficit of
visual acuity in one eye, it is most commonly found in
association with squint or anisometropia (unequal refract-
ive error between eyes), or both. Historically, a diverse
range of physical and pharmacological treatments have
been prescribed [2], and although novel treatments con-
tinue to emerge (for example, those involving visual
stimulation) [3-5], occlusion of the nonamblyopic eye,
most commonly by an adhesive fabric patch, remains the
treatment of preference [6].
For the most part of the twentieth century, the efficacy
of occlusion went unquestioned and it was only with the
championing of evidence-based medicine in the 1990s
[7] that its effectiveness became the subject of systematic
investigation [2,8]. One strand of observational research
has sought to determine mathematically the relationship
(‘dose response’) between the amount of patching and
any subsequent change in visual acuity. Such studies
were facilitated by the introduction of the occlusion dose
monitor by Fielder and colleagues in 1994 [9,10]. This
device permitted, for the first time, objective records of
patching episodes to be obtained from children undergo-
ing treatment. Using this device, two principal studies,
MOTAS and ROTAS [11,12], have provided insight into
the dose-response relationships of occlusion therapy and
how these vary as a function of amblyopia type, age of
patient, and severity of the condition. The findings of
these studies have largely been confirmed by traditional
randomized trials [13] and have helped to identify opti-
mal treatment regimens for use in clinical practice.
A practical consequence of this research has been a
trend away from ad-hoc patching regimens (anything from
a few minutes per day up to all waking hours) towards a
more standardized approach (now gradually being incorpo-
rated into practice guidelines [14]). Thus, it is now possible
to elicit consensus among expert practitioners as to what
presently constitutes best practice, that is, in the amount of
patching that should be prescribed to an initially presenting
amblyopic child. In this Randomized Occlusion Dosing
Strategies (RODS) trial, the occlusion regimens prescribed
in one of the treatment arms (the standardized dosing strat-
egy) represents the current prevailing clinical opinion of a
representative group of UK orthoptists.
The rationale behind RODS is the notion that further
refinements in prescribing may yield improvements in
outcome. By examining the dose-response relationships
determined for the amblyopic children taking part in
MOTAS [11] and ROTAS [12], we have generated a stat-
istical model that allows us to estimate, on the basis of
the severity of the initially presenting amblyopia, the age
of the patient, and the type of amblyopia, the amount(total hours) of occlusion required to treat any given am-
blyopic child. This we term the ‘total effective dose’, which
for any given treatment period can be converted into a
daily dose-rate (hours per day) and subsequently increased
or decreased depending on compliance. We term this ap-
proach a ‘personalized dosing strategy’.
In summary, the protocol described herein has been
designed to test the hypothesis that superior clinical out-
comes will be obtained with a personalized dosing strategy
compared with a standardized dosing strategy (in which
all patients receive an occlusion regimen based upon
current best practice).
Methods/design
Objectives of the study
The primary study objective is to determine whether
study participants in receipt of a personalized dosing
strategy reach trial endpoint (optimal visual acuity) in a
shorter period of time, and with reduced variance, than
those in receipt of a standardized dosing strategy.
The secondary study objectives are:
1. To determine the relationship between observed
changes in logMAR visual acuity as a function of:
 Objectively monitored occlusion dose,
 Type of amblyopia,
 Age of participant.
2. To determine whether compliance differs between
standardized and personalized dosing strategy
treatment arms.
Eligibility criteria
Inclusion criteria
 Male or female,
 Aged 3 to 8 years inclusive,
 Visual acuity of 0.10 logMAR or higher (poorer
acuity) in the worst (amblyopic) eye,
 Interocular difference in acuity of at least 0.20
logMAR,
 Presence of anisometropia or strabismus (or both),
 Knowledge of the extent of spectacle wear (if any)
prior to trial entry,
 Parent or guardian willing and able to give informed
consent for participation in the study,
 Cognitive, motor and verbal skills of sufficient maturity
to undergo visual acuity testing with letter optotypes.
Exclusion criteria
 Comorbid ocular disease (including amblyopia
associated with form deprivation),
 Prior occlusion therapy for amblyopia,
 Evidence of learning difficulties or developmental delay.
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The study is a randomized, parallel group, unmasked
design, as depicted in Figure 1. Each study arm comprises
three sequential phases: initial assessment, optical treat-
ment (common to each respective study arm) and occlu-
sion (either standardized or personalized dosing strategy
in respective study arms).
Dosing strategies
Standardized dosing strategy
In the standardized dosing strategy arm, participants are
prescribed one of three dosing regimens dependent on
their visual acuity at the end of the optical treatment
phase. These dosing regimens were the consensus out-
come, initially of formal face-to-face discussion, between
eight senior orthoptists identified by membership of the
British and Irish Orthoptic Society, and drawn from
geographically diverse areas of the United Kingdom. All
experts had a minimum of 10 years’ clinical experience.
Discussion focused on the management of six clinical
scenarios representative of cases meeting the RODS eli-
gibility criteria. The experts’ views of how each scenario
should be managed were appraised by the panel con-
vener (CES) and a series of dosing regimens was de-
rived. These regimens were subsequently reviewed by
the panel and their suitability unanimously confirmed
by all members as follows:
 Mild amblyopia (<0.4 logMAR): 2 hours per day,
 Moderate amblyopia (0.4 to <0.8 logMAR): 3 hours
per day,
 Severe amblyopia (≥0.8 logMAR): 5 hours per day.
Personalized dosing strategy
In the personalized dosing strategy arm, participants are
prescribed an initial occlusion dose determined by their
age, type, and severity of amblyopia, based upon dose-
response functions derived from previous studies involving
participants of near-identical clinical and demographic sta-
tus to those enrolled in the present trial [11,12]. As partici-
pants in this arm progress through the occlusion phase,
the prescribed occlusion dose is modified at each clinic
visit, depending on treatment compliance, and is predi-
cated on the notion of a total effective dose: the minimum
amount of occlusion that should result in an optimal visual
outcome.
The rationale underpinning treatment by a personalized
dosing strategy is an attempt to define a patient’s total oc-
clusion dose, which can then be converted to a daily
patching regimen on the presumption of a fixed treatment
period. We make the assumption that every patient has
some optimal visual outcome that they can hope to
achieve, and that there exists some total effective dose of
occlusion that must be received in order to achieve it.Furthermore, we assume that any dose received by a pa-
tient in excess of this total effective dose is ‘wasted’: it does
not improve the patient’s visual acuity any further, as it is
impossible to improve beyond the patient’s optimal visual
outcome. For example, if a patient’s total effective dose is
200 hours, then that patient will have the same visual out-
come after 200, 250, or even 1,000 hours of occlusion.
However, the patient’s visual improvement would be
limited if fewer than this 200 hours of occlusion were
achieved. Employing mathematical notation, we can say
that patient i has some optimal visual acuity Vi
*, which
will be achieved if, and only if, patient i undertakes at
least Di
* hours of occlusion. Our aim is to construct a
model that predicts this Di
* based on an analysis of
known treatment-response functions [11,12]. To con-
strain the complexity of the model (and in the absence
of compelling evidence to the contrary) it is assumed
that the total effective dose is dose-rate independent,
that is, a single occlusion dose is of equivalent effect-
iveness to multiple individual doses that sum to the
same total number of hours.
Predictions of Di
* were derived from a normal linear
interval regression model with the total effective dose of
some patient i with initial residual amblyopia Ri and age
Ai estimated by the formula:
Di ¼ ð18:150þ 16:122Ri–0135Ai–0:547TM–8:028TS
–12:176RiTM–11:334RiTS þ 0:065AiTM þ 0:192AiTSÞ2
where TM and TS are indicator functions taking the
value 1 if the patient has mixed or strabismic amblyopia,
respectively, or 0 otherwise.
In practice, participants in the personalized dosing
strategy arm have their total effective dose estimated on
an assumed fixed follow-up period of 12 weeks, which
results in manageable dose-rates. Therefore, an individ-
ual patient’s personalized daily patching regimen will be
calculated by first estimating the total effective dose and
then dividing this by the number of days left in the
follow-up period. For reasons of practicality, we only
prescribe daily patching episodes rounded up to the
nearest 30 minutes. Dose-rate can then be updated at
follow-up appointments based on how much occlusion
has been objectively recorded. To avoid the prescription
of subtherapeutic doses of occlusion, the model is con-
strained such that dose-rates less than 2 hours per day
are never prescribed. Of course, patients will probably
be treated for a period longer than 12 weeks, as the
follow-up sessions will be continued until the visual acu-
ity criteria for study exit have been met. Therefore, once
a patient passes the tenth week of follow-up, all future
daily prescription calculations will assume a 2-week
follow-up period until treatment is completed.
Figure 1 Study participant flow.
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patient who enters occlusion aged 48 months with residual
amblyopia of 0.5 logMAR and amblyopia associated withanisometropia. Using the formula derived from our model,
the estimated total effective dose would be 389 hours. Over
a 12-week follow-up period, this requires an average daily
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5 hours of occlusion a day. At a follow-up appointment
2 weeks later, the patient has only undertaken 30 hours of
occlusion (rather than the prescribed 70). The patient’s total
effective dose reduces from 389 to 359 hours, but with only
10 weeks left of the initial follow-up period the patient
must now average 5.1 hours of occlusion a day. Thus, our
prescribed dose-rate increases to 5.5 hours a day.
Recruitment sites
Potential study participants are initially identified
from new patients attending orthoptic departments
at Hillingdon Hospital, Hillingdon, UK and Princess
Alexandra Hospital, Harlow, UK.
Trial phases
Initial assessment phase
Attending patients undergo a full orthoptic and oph-
thalmic examination, including cycloplegic refraction.
Where clinically significant refractive error is found,
spectacles are prescribed (full corrections for astig-
matic, anisometropic myopic and mild or moderate
hypermetropic (+2.00 to +5.00) and within 2 dioptres
of the full correction for high hypermetropic errors).
Clinically significant refractive error is defined as:
 ≥1.50 dioptres sphere bilateral hypermetropia,
 ≥1.50 dioptres sphere bilateral myopia,
 ≥0.75 dioptres cylinder bilateral astigmatism,
 All astigmatism in combination with hypermetropia,
 ≥1.00 dioptres sphere anisometropia.
The parents or guardians of those children meeting
the study’s eligibility criteria are provided with an infor-
mation sheet and, subject to verbal consent, invited to
attend an appointment (start of trial) with a research
orthoptist (CES or LCS). They are asked to bring with
them (but not to have their child previously wear) any
spectacles dispensed as an outcome of the current
consultation.
Optical treatment phase
Written informed consent is sought from the parents or
guardians of all potentially participating children at the
outset of this phase. Except for those children not pre-
scribed spectacles in the initial assessment phase (who
progress directly to the occlusion phase), participants
are instructed to wear their spectacles full time and to
return for vision assessment at 6-weekly intervals from
week 0 (onset of spectacle wear) until 18 weeks of optical
treatment is complete (a period that allows for all signifi-
cant improvement attributable to spectacle wear to have
occurred [15]). If there is a significant improvement (≥0.1
logMAR) between weeks 12 and 18, the participants areasked to wear their spectacles for further 6-week periods
until significant gains have ceased. If participants have
worn spectacles for refractive correction prior to study
entry, the number of weeks for which spectacles were pre-
viously worn is documented; a minimum of 18 weeks (in
total) wear is required before progression to the next study
phase. It is anticipated that around 20 to 25% of partici-
pants will, by the end of this phase, have obtained equal
eye acuity and will leave the trial at this point.
As a safeguard, should significant deterioration in acuity
occur (defined as loss of more than 0.20 logMAR from any
previous testing), the child will undergo a repeat cycloplegic
refraction and the prescription will be changed if there is a
significant difference from the initial prescription, before re-
commencing in this study phase. If no discrepancy is ob-
served, in the presence of sustained deterioration in vision,
the child shall be withdrawn from the trial. If a pathological
cause of the vision loss is suspected, the child is referred
back to the ophthalmologist at the local site for continued
clinical care.
Occlusion phase
On entering this phase, study participants are randomly
assigned (stratified by geographic site and amblyopia
type) to either the personalized or standardized dosing
strategy arms of the trial using an online true random
number generator [16].
Participants will have their visual acuity recorded every
2 weeks until the trial endpoint is reached. To provide a
check against the unmasked nature of the study design,
visual acuity is further recorded at the end of the occlu-
sion phase by an examiner masked to the participants’
treatment arms.
Occlusion dose monitoring
All study participants who progress to the occlusion
phase have their prescribed patch wear (standardized
or personalized dosing strategy) objectively monitored
using an occlusion dose monitor. Briefly, this device
monitors, and records electronically, episodes of patch-
skin contact indicative of patch wear. At the scheduled
clinic visits, the occlusion dose monitor is interrogated
via a PC to provide a time history of patching episodes
from which daily (‘dose-rate’) and accumulated (‘dose’)
occlusion can be derived. A full description of the occlu-
sion dose monitor’s construction and mode of operation
has been reported elsewhere [9,10].
Endpoint determination and sample size calculation
Participants complete the trial at that point in the occlusion
phase at which equal visual acuity of each eye is achieved,
or if vision has stabilized (defined as three inflexions in a
plot of acuity against time or remaining unchanged over
three consecutive visits). All children wear occlusion for a
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gains in visual acuity are observed. A sample size of 60 in
each arm at 95% power and with a type I error rate of 0.05
corresponds to a Cohen’s d statistic of 0.605. The log-
transformed time to best visual acuity across MOTAS [11]
and ROTAS [12] was approximately normally distributed
and had a mean (standard deviation) of 4.0133 (0.801).
We could therefore expect to detect a difference of
around 21 days in mean time to best visual acuity in
our two groups.
Outcomes and analyses
Primary outcome and its measurement
The primary outcome variable is logMAR visual acuity
assessed on one or more of the following test charts:
crowded logMAR, uncrowded logMAR, or modified
ETDRS.
The crowded and uncrowded logMAR charts are
viewed at a test distance of 3 m and comprise six letters,
X V O H U Y, which were selected for their approxi-
mately equal legibility. There are four letters on each
line, which provide a constant visual demand at each
level of acuity. Each letter correctly read can be scored
by interpolation as 0.025 logMAR with an acuity range
of 0.800 to −0.300 logMAR (6/38 to 6/3), which can be
extended to 1.4 to −0.300 logMAR by employing a log
increment step reduction in viewing distance. Letter spa-
cing is equal to 0.5 letter diameters. In the crowded
chart, a black printed rectangle surrounds each row of
letters at 0.5 letter diameters distance and of equivalent
width to the letter height.
The modified ETDRS chart is viewed at a test distance
of 4 m, giving an acuity range of 1.00 to −0.30 logMAR
(6/60 to 6/3). This test range can be extended to 1.60
logMAR by reducing the viewing distance in log incre-
mental steps. Each line comprises five letters and is
scored on a letter-by-letter basis, providing interpolated
acuity values of 0.02 logMAR resolution.
The chart used depends on the reading ability of the
child and is generally age-dependent. The visual acuity
test used in the initial assessment phase will be used
throughout the trial period; however, if a child is judged
able to progress to a more difficult test, this test will
additionally be employed for the remainder of the trial.
Visual acuity of the amblyopic eye is always recorded
first; the rationale being that amblyopic eye visual acuity
is the principal outcome variable and the visual acuity of
this eye should be tested when the child is maximally
alert and free of fatigue.
Analyses
The primary study objective of comparing time to best
visual acuity between the two treatment groups, along
with the secondary objective of comparing compliance,will be analyzed via standard t tests (to compare length
of time and compliance) and Levene’s test (to compare
variance in time). Suitable nonparametric alternatives
will be used should concerns arise regarding the neces-
sary distributional assumptions for these methods. The
secondary objective to determine the relationship be-
tween changes in visual acuity and dose, amblyopia type,
and age, will be investigated using standard regression
modelling approaches.
Ethical approval and conduct
Ethical approval for the trial was granted by The
National Research Ethics Service Committee London,
Bloomsbury, protocol No. PB-PG-0808-16087.
Discussion
The trial protocol described herein aims to compare two
means of prescribing occlusion therapy for childhood
amblyopia. One trial arm (standardized dosing strategy)
is considered representative of current best practice in
the UK, the other (personalized dosing strategy), a regimen
with an empirical basis formulated using a statistical mod-
elling approach of documented patient response data. To
the best of our knowledge, the personalized dosing strategy
is an entirely novel approach to undertaking occlusion ther-
apy, with a significant potential benefit of a reduction in the
amount of treatment needed. This advantage goes beyond
any anticipated economic benefit and bears directly on the
unpleasantness of occlusion for children and the corre-
sponding difficulty parents have in achieving compliance
(objective estimates of occlusion received are less than half
those prescribed [17]). Hence, the personalized dosing
strategy is underpinned by the notion of a total effective
dose: a prescription of occlusion that is sufficient and not
excessive and is informed on a prospective basis by an indi-
vidual’s compliance (actual dose received).
It is necessary to emphasize that the implementation
of a personalized dosing strategy (either that developed
for the present trial or future modifications of it) is entirely
dependent on the use of occlusion dose monitoring. This
important advance has hitherto been entirely confined to
use within formalized research studies and is not used
routinely in clinical practice despite the seemingly obvious
advantages it brings in providing feedback to clinicians
and parents. A demonstration of the superiority of the
personalized dosing strategy approach would undoubtedly
provide an incentive for its take-up in the clinic.
Trial status
Participant enrolment commenced in October 2013 and
the trial is scheduled to complete by December 2015.
Abbreviations
logMAR: logarithm of the Minimum Angle of Resolution; RODS: Randomized
Occlusion Dosing Strategies.
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